X T L Biopharmaceuticals (NASDAQ:XTLB) and Kalvista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations.
Insider & Institutional Ownership
9.0% of X T L Biopharmaceuticals shares are owned by institutional investors. Comparatively, 80.6% of Kalvista Pharmaceuticals shares are owned by institutional investors. 38.4% of Kalvista Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This is a summary of current ratings and recommmendations for X T L Biopharmaceuticals and Kalvista Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|X T L Biopharmaceuticals||0||0||0||0||N/A|
Kalvista Pharmaceuticals has a consensus price target of $31.75, indicating a potential upside of 65.80%. Given Kalvista Pharmaceuticals’ higher possible upside, analysts clearly believe Kalvista Pharmaceuticals is more favorable than X T L Biopharmaceuticals.
Earnings & Valuation
This table compares X T L Biopharmaceuticals and Kalvista Pharmaceuticals’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|X T L Biopharmaceuticals||N/A||N/A||$2.99 million||N/A||N/A|
|Kalvista Pharmaceuticals||$8.39 million||39.37||-$15.80 million||($1.53)||-12.52|
X T L Biopharmaceuticals has higher earnings, but lower revenue than Kalvista Pharmaceuticals.
This table compares X T L Biopharmaceuticals and Kalvista Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|X T L Biopharmaceuticals||N/A||67.12%||65.44%|
Volatility and Risk
X T L Biopharmaceuticals has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Kalvista Pharmaceuticals has a beta of 2.22, indicating that its share price is 122% more volatile than the S&P 500.
Kalvista Pharmaceuticals beats X T L Biopharmaceuticals on 6 of the 11 factors compared between the two stocks.
About X T L Biopharmaceuticals
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Ramat Gan, Israel.
About Kalvista Pharmaceuticals
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, an intravitreally administered plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein, which is in Phase I clinical trial for treating HAE. The company is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for X T L Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X T L Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.